Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis (AD)
Conditions
Interventions
KHK4083
Placebo
Locations
58
United States
Kyowa Investigational Site US-19
Huntington Beach, California, United States
Kyowa Investigational Site US-17
Irvine, California, United States
Kyowa Investigational Site US-09
Los Angeles, California, United States
Kyowa Investigational Site US-05
Santa Ana, California, United States
Kyowa Investigational Site US-10
Aurora, Colorado, United States
Kyowa Investigational Site US-14
Clearwater, Florida, United States
Start Date
October 22, 2018
Primary Completion Date
February 6, 2020
Completion Date
November 12, 2020
Last Updated
April 26, 2024
NCT07262983
NCT06389136
NCT06342713
NCT07290803
NCT07223697
NCT07265479
Lead Sponsor
Kyowa Kirin, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions